RT Journal Article SR Electronic T1 Combined Metabolic Activators Improves Cognitive Functions in Alzheimer’s Disease JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.07.14.21260511 DO 10.1101/2021.07.14.21260511 A1 Burak Yulug A1 Ozlem Altay A1 Xiangyu Li A1 Lutfu Hanoglu A1 Seyda Cankaya A1 Simon Lam A1 Hong Yang A1 Ebru Coskun A1 Ezgi İdil A1 Rahim Nogaylar A1 Cemil Bayram A1 Ismail Bolat A1 Sena Öner A1 Özlem Özdemir Tozlu A1 Mehmet Enes Arslan A1 Ahmet Hacımuftuoglu A1 Serkan Yıldırım A1 Muhammad Arif A1 Saeed Shoaie A1 Cheng Zhang A1 Jens Nielsen A1 Hasan Turkez A1 Jan Borén A1 Mathias Uhlén A1 Adil Mardinoglu YR 2021 UL http://medrxiv.org/content/early/2021/07/20/2021.07.14.21260511.abstract AB Alzheimer’s disease (AD) is associated with metabolic abnormalities linked to critical elements of neurodegeneration. Here, we analyzed the brain transcriptomics data of more than 600 AD patients using genome-scale metabolic models and provided supporting evidence of mitochondrial dysfunction related to the pathophysiologic mechanisms of AD progression. Subsequently, we investigated, in an animal model of AD, the oral administration of Combined Metabolic Activators (CMAs), consisting of NAD+ and glutathione precursors, to explore the effect for improvement of biological functions in AD. CMAs includes L-serine, nicotinamide riboside, N-acetyl-L-cysteine, and L-carnitine tartrate, salt form of L-carnitine. The study revealed that supplementation of the CMAs improved the AD-associated histological parameters in the animals. Finally, we designed a randomized, double-blinded, placebo-controlled human phase 2 study and showed that the administration of CMAs improves cognitive functions in AD patients. A comprehensive analysis of the human plasma metabolome and proteome revealed that plasma levels of proteins and metabolites associated with redox metabolism are significantly improved after treatment. In conclusion, our results show that treating AD patients with metabolic activators leads to enhanced cognitive functions, suggesting a role for such a therapeutic regime in treating AD and other neurodegenerative diseases.Competing Interest StatementAM, JB and MU are the founder and shareholders of ScandiBio Therapeutics. The other authors declare no competing interests. Clinical TrialNCT04044131Funding StatementThis work was financially supported by ScandiBio Therapeutics and Knut and Alice Wallenberg Foundation. The authors would like to thank the Metabolon Inc. (Durham, USA) for generation of metabolomics data, and ChromaDex Inc. (Irvine, CA, USA) for providing NR. AM and HY acknowledge support from the PoLiMeR Innovative Training Network (Marie Sklodowska-Curie Grant Agreement No. 812616) which has received funding from the European Union's Horizon 2020 research and innovation programme. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ethics committee approved the study of Istanbul Medipol University, Istanbul, Turkey, and retrospectively registered at https://clinicaltrials.gov/ with Clinical Trial ID: NCT04044131. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll available data included in the supplementary datasets.